首頁 > 市場調查報告書 > 製藥

動物用醫藥

市場調查報告書

商品編碼

1295381

動物人類藥物市場 - 預測 2023-2028

Human Drugs for Veterinary Use Market - Forecasts from 2023 to 2028

出版日期: 2023年06月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 104 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

獸用人藥市場預計將以 2.90% 的複合年增長率增長，從 2021 年的 33.57 億美元增長到 2028 年的 41.02 億美元。動物接受人類藥物治療，但它們可能會受到與人類相同的影響。儘管藥物在動物身上進行了用於人類的測試，但這些影響是已知的。製藥公司為人類生產的藥物多於為動物生產的藥物。止痛藥加巴噴丁和普瑞巴林（Lyrica）在狗和馬身上超說明書使用，是獸醫醫學中經常推薦的人類藥物的例子。

此外，還使用麻醉劑，例如芬太尼、嗎啡、美沙酮、氫嗎啡酮、氯胺酮、丁丙諾啡和氫可酮。也可以使用曲馬多，但動物的處方劑量高於人類，因為動物的代謝不同。此外，動物慢性疾病患病率的上升、生產動物數量的增加、寵物和家禽主人吸毒習慣的增加，加上人口的持續增長，正在推動增長。

寵物飼養趨勢正在推動獸藥行業的發展。

因此，對獸藥和藥品的需求將會增加。此外，研究計劃資金的增加可能會推動未來幾年及以後的行業擴張。抗生素耐藥性是健康動物不必要地使用抗生素造成的危險。隨著心臟病、糖尿病和癌症等健康問題的增加，耐藥疾病的出現和傳播威脅著動物治療動物的能力。此外，隨著狗和貓等動物體內寄生蟲引起的疾病數量不斷增加，寵物主人可能會使用抗寄生蟲藥物來控制和預防疾病。例如，寵物食品製造商協會(PFMA) 報告稱，到2021 年，英國將有1700 萬個家庭(59%) 養寵物，而PFMA 的2022 年報告指出，到2022 年，將有1740 萬個家庭養寵物。此外，根據美國寵物產品協會的報告，2021年美國將有6900萬狗主人和4530萬貓主人。

此外，許多國家的政府都制定了嚴格的法律，並開展了廣泛的疫苗接種和禁毒運動。例如，2022年1月，《獸藥條例》生效。這是歐盟(EU) 針對抗菌素耐藥性(AMR) 採取的行動，將促進創新，為獸醫、農民和寵物主人提供安全、優質的藥物，以管理和預防動物疾病。它支持採取新措施，提高可及性和可及性。的可用性

預計抗生素領域將佔據重要的市場份額。

按藥物分為抗生素、非甾體抗炎藥、阿片類鎮痛藥、化療藥等。動物生產設施過度擁擠、衛生習慣不良以及抗生素耐藥細菌的出現等因素正在增加傳染病的發病率。根據《Veterinary Microbiology》雜誌上發表的一項研究，細菌性呼吸道感染在牲畜中很常見，造成經濟損失和動物福利不佳。這增加了對有效抗生素來對抗這些感染和保護動物健康的需求。此外，分子生物學方法和快速POC檢測等診斷技術的改進提高了準確識別和診斷牲畜細菌感染的能力。這有助於有針對性的抗生素治療並確保適當的治療。

由於越來越多的獸醫醫院提供按服務收費的治療，北美市場正在擴大。

按地區劃分，全球獸藥和人用藥品市場分為北美、南美、歐洲、亞太地區以及中東和非洲。美國同伴數量的增加正在加速，進一步增加了獸藥的消費量。美國是認識到動物對人類藥物有類似反應的先驅。用人類藥物治療動物，動物的效果與人類相似。用人類藥物治療動物，對動物的作用與對人類的作用相同。儘管動物和人類藥物的生產存在差異，但用相似類型的藥物治療這些疾病也有一線希望。斯坦福大學的一項研究發現，小鼠和人類的 DNA 98% 相似。事實證明，患病的可能性是一樣的。癌症、糖尿病和心臟病病例是人類和小鼠的複製品。該研究隨後發表，美國聯邦法律允許使用人類藥物來治療常見的人類和動物疾病。

市場趨勢：

FDA 已批准青黴素用於獸用。
2022 年 4 月，Elanco Animal Health Incorporated 和 Ginkgo Bioworks 成立了一家新公司 BiomEdit，為動物創造新的創新治療產品。Ginkgo Bio 是美國最成功的生物技術公司之一。

The human drugs for veterinary use market is expected to grow at a CAGR of 2.90% from US$3.357 billion in 2021 to US$4.102 billion by 2028. Animals are treated with human medications, which may have the same effects on them as they do on humans. While drugs are tested on animals for human use, these consequences are known. Pharmaceutical companies produce more medications for humans than for animals. Additionally, physicians treat animals with extra-label human medicines due to the disparity in industry sales and growth/ The painkillers gabapentin and pregabalin (Lyrica), used off-label in dogs and horses, are examples of human-labeled pharmaceuticals that are frequently recommended in veterinary medicine.

Additionally used are narcotics such as fentanyl, morphine, methadone, hydromorphone, ketamine, buprenorphine, and hydrocodone. Tramadol can also be employed; however, because of differences in animal metabolism, bigger doses for animals are prescribed than for humans. Moreover, the rising prevalence of chronic diseases in animals, the growing population of production animals, and an increase in drug habits among pet and poultry business owners, combined with consistent human population growth, are the factors driving the growth.

The trend toward pet ownership is driving the animal health industry.

As a result, there will be an increase in demand for animal medicines and drugs. Additionally, increased financing for research initiatives will fuel industry expansion in the ensuing years and beyond. Antibiotic resistance is a danger caused by the unnecessary use of antibiotics on healthy animals. With rising health problems like heartworm, diabetes, and cancer, the introduction and spread of drug-resistant diseases threaten the ability to treat animals. Further, the use of parasiticides by pet owners for disease management and prevention is likely to increase as cases of parasite-caused illness in dogs, cats, and other animals rise. For instance, the Pet Food Manufacturers Association (PFMA) reported that 17 million (59%) households in the United Kingdom had pets in 2021, and the PFMA 2022 report predicted that 17.4 million households had pets in 2022. Additionally, the number of dog and cat owners in the United States are 69 million and 45.3 million, respectively, in 2021, as per the American Pet Products Association report.

Further, the governments of numerous nations are putting strict laws along with widespread vaccination and drug campaigns. For instance, in January 2022, the regulation on veterinary medicinal products came into effect. It supports the European Union's (EU) action towards antimicrobial resistance (AMR) and new measures for promoting innovation and boosting accessibility and availability to safe and high-quality medications for veterinarians, farmers, and pet owners to manage and prevent animal diseases.

The antibiotics segment is expected to hold a considerable market share.

By medication, the human drugs for veterinary use market is divided into antibiotics, non-steroidal anti-inflammatories, opioid pain relievers, chemotherapeutics, and others. Factors such as overcrowding in animal production facilities, poor hygiene practices, and the emergence of antibiotic-resistant bacteria have contributed to the higher incidence of infections. According to a study published in Veterinary Microbiology, bacterial respiratory infections are common in livestock, causing economic losses and compromising animal welfare. This has increased the demand for effective antibiotics to combat these infections and safeguard animal health. Moreover, Improved diagnostic techniques, including molecular methods and rapid point-of-care tests, have enhanced the ability to identify and diagnose bacterial infections in animals accurately. This facilitates targeted antibiotic therapy and ensures appropriate treatment.

The North American market is expanding because of more veterinary facilities providing reimbursement.

By geography, the global human drug for veterinary use market has been classified into North America, South America, Europe, Asia Pacific, and Middle East, and Africa. The trend of growing companionship is increasing in the US, and the consumption of veterinary products is rising further. The United States became a pioneer in recognizing that animals might react similarly to human medicines. Animals are treated with human medications, which have the same effects on them as they do on humans. Animals are treated with human medicines, which have the same impact on them as they do on humans. Although there is a disparity in the production of drugs for animals and humans, there has been a silver lining in treating these diseases with a similar type of drug. In a study by Stanford recently, 98% DNA of a mouse and a human was found to be similar. The possibility of diseases was also found to be identical. Cases of cancer, diabetes, and heart disease were replicas of humans and mice. After that, the study was published, and the US Federal law permitted using human medicines to treat common illnesses in humans and animals.

Market Developments:

FDA approved the use of penicillin for animals which was earlier used only for humans.
In April 2022, Elanco Animal Health Incorporated and Ginkgo Bioworks launched a new company, BiomEdit, to make new and innovative treatment products for animals. Ginkgo Biotech is one of the most successful biotech companies in the US.

Market Segmentation:

By Medication Type

Antibiotics
Non-steroidal anti-inflammatories
Opioid pain relievers
Chemotherapeutics
Others

By Drug type

Penicillin
Prednisone and Prednisolone
Diazepam
Prozac
Others

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Others
Middle East and Africa
Saudi Arabia
Israel
Others
Asia Pacific
China
Japan
India
South Korea
Indonesia
Thailand
Taiwan
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.3.6. Industry Value Chain Analysis

5. HUMAN DRUGS FOR VETERINARY USE MARKET BY MEDICATION TYPE

5.1. Introduction
5.2. Antibiotics
5.3. Non-steroidal anti-inflammatories
5.4. Opioid pain relievers
5.5. Chemotherapeutics
5.6. Others

6. HUMAN DRUGS FOR VETERINARY USE MARKET BY DRUG TYPE

6.1. Introduction
6.2. Penicillin
6.3. Prednisone and Prednisolone
6.4. Diazepam
6.5. Prozac
6.6. Others

7. HUMAN DRUGS FOR VETERINARY USE MARKET BY GEOGRAPHY

7.1. Introduction
7.2. North America
- 7.2.1. USA
- 7.2.2. Canada
- 7.2.3. Mexico
7.3. South America
- 7.3.1. Brazil
- 7.3.2. Argentina
- 7.3.3. Others
7.4. Europe
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Others
7.5. Middle East and Africa
- 7.5.1. Saudi Arabia
- 7.5.2. Israel
- 7.5.3. Others
7.6. Asia Pacific
- 7.6.1. China
- 7.6.2. Japan
- 7.6.3. India
- 7.6.4. South Korea
- 7.6.5. Indonesia
- 7.6.6. Thailand
- 7.6.7. Taiwan
- 7.6.8. Others